Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition. Researchers and clinicians can now go beyond genetics, combining proteomics, metabolomics, transcriptomics, and environmental factors into a broad category of human data. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.
With a whole host of patient data at our fingertips, drug developers are becoming more thoughtful and strategic in developing medicines and designing clinical trials to test them. In this episode we talk to Rob Lenz, Senior Vice President of Global Development at Amgen. We review the full scope of human data, going beyond the genome to explore the challenges of using human data as well as the opportunities of applying human data to drug research and clinical trials.
To dive further into this topic, please join Amgen scientists at the Human Data Era Q&A webinar discussion on November 16, 2022. Register for the event here.